Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Topcoin

Rank: Treasurer [?]

Points: 462 [?]

Votes: 6 Score: 3.0 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

in response to

Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL

tada

posted on Nov 22, 2018 01:42PM

Yes I can confirm that 3694 has been tested with Apalutamide . DM confirmed this to me when I asked. Aberaterone going generic may actually broaden its use as price will come down and 3694 combo use might increase as well ?

6 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply